CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 75 enrolled
Drug / intervention
Uridine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03265964
NCT03265964Phase 4Completed
CompareCT.gov

Clinical and Imaging Biomarker Trial of Uridine for Veterans With Suicidal Ideation

VA Office of Research and Development·interventional·Posted Aug 29, 2017·Updated Aug 15, 2025

In Brief

A Phase 4 clinical trial evaluating Uridine and Placebo for Suicidal Ideation. Completed, enrolled 75 participants across 1 site.

Detailed Summary

This is a randomized, double-blind, placebo-controlled study of the investigational drug uridine as a treatment for suicidal ideation in veterans. The investigators hypothesize that the administration of a naturally occurring dietary supplement, uridine, will rapidly reduce suicidal ideation in veterans. The purpose of this study is to determine whether 4 weeks of uridine supplementation is an effective treatment for suicidal ideation in veterans, when compared to a group taking a placebo.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSuicidal Ideation
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedAug 29, 2017
Enrollment StartApr 2, 2018
Primary CompletionJun 30, 2024
TodayJul 2, 2026
Enrollment to primary: 6.2 yearsPosted 8.8 years ago

Interventions

Uridinedrug

Uridine is the active treatment in this clinical trial.

Placebodrug

Pill placebo is the inactive treatment comparator in this clinical trial.